James Jones - Dec 1, 2022 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
James Jones by /s/ John Hamm as attorney-in-fact
Stock symbol
CPIX
Transactions as of
Dec 1, 2022
Transactions value $
$1,487
Form type
4
Date filed
12/23/2022, 04:11 PM
Previous filing
Dec 23, 2022
Next filing
Mar 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Purchase $72.20 +31 +0.12% $2.33 25.7K Dec 1, 2022 Direct F1
transaction CPIX Common Stock Purchase $71.60 +31 +0.12% $2.31 25.7K Dec 2, 2022 Direct F1
transaction CPIX Common Stock Purchase $67.90 +31 +0.12% $2.19 25.7K Dec 5, 2022 Direct F1
transaction CPIX Common Stock Purchase $67.90 +31 +0.12% $2.19 25.8K Dec 6, 2022 Direct F1
transaction CPIX Common Stock Purchase $67.60 +31 +0.12% $2.18 25.8K Dec 7, 2022 Direct F1
transaction CPIX Common Stock Purchase $67.90 +31 +0.12% $2.19 25.8K Dec 8, 2022 Direct F1
transaction CPIX Common Stock Purchase $66.70 +31 +0.12% $2.15 25.8K Dec 9, 2022 Direct F1
transaction CPIX Common Stock Purchase $66.30 +31 +0.12% $2.14 25.9K Dec 12, 2022 Direct F1
transaction CPIX Common Stock Purchase $87.20 +40 +0.15% $2.18 25.9K Dec 13, 2022 Direct F1
transaction CPIX Common Stock Purchase $88.40 +40 +0.15% $2.21 26K Dec 14, 2022 Direct F1
transaction CPIX Common Stock Purchase $44.80 +20 +0.08% $2.24 26K Dec 15, 2022 Direct F1
transaction CPIX Common Stock Purchase $88.80 +40 +0.15% $2.22 26K Dec 16, 2022 Direct F1
transaction CPIX Common Stock Purchase $155 +70 +0.27% $2.21 26.1K Dec 19, 2022 Direct F1
transaction CPIX Common Stock Purchase $280 +121 +0.46% $2.31 26.2K Dec 20, 2022 Direct F1
transaction CPIX Common Stock Purchase $195 +88 +0.34% $2.22 26.3K Dec 21, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.